These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31881024)

  • 1. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
    Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF
    PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
    Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
    Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.
    Karpman D; Papadopoulou D; Nilsson K; Sjögren AC; Mikaelsson C; Lethagen S
    Blood; 2001 May; 97(10):3100-8. PubMed ID: 11342436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.
    Nolasco LH; Turner NA; Bernardo A; Tao Z; Cleary TG; Dong JF; Moake JL
    Blood; 2005 Dec; 106(13):4199-209. PubMed ID: 16131569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.
    Karpman D; Tati R
    Kidney Int; 2016 Oct; 90(4):726-9. PubMed ID: 27633864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
    Zoja C; Buelli S; Morigi M
    Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.
    Ståhl AL; Sartz L; Nelsson A; Békássy ZD; Karpman D
    PLoS One; 2009 Sep; 4(9):e6990. PubMed ID: 19750223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
    Bowen EE; Hurcombe JA; Barrington F; Keir LS; Farmer LK; Wherlock MD; Ortiz-Sandoval CG; Bruno V; Bohorquez-Hernandez A; Diatlov D; Rostam-Shirazi N; Wells S; Stewart M; Teboul L; Lay AC; Butler MJ; Pope RJP; Larkai EMS; Morgan BP; Moppett J; Satchell SC; Welsh GI; Walker PD; Licht C; Saleem MA; Coward RJM
    Med; 2023 Nov; 4(11):761-777.e8. PubMed ID: 37863058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Taylor FB
    J Am Soc Nephrol; 2001 Jul; 12(7):1458-1467. PubMed ID: 11423574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
    Zoja C; Buelli S; Morigi M
    Pediatr Nephrol; 2010 Nov; 25(11):2231-40. PubMed ID: 20424866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
    Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
    J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Abrey Recalde MJ; Alvarez RS; Alberto F; Mejias MP; Ramos MV; Fernandez Brando RJ; Bruballa AC; Exeni RA; Alconcher L; Ibarra CA; Amaral MM; Palermo MS
    Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29068360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
    Pysher TJ; Siegler RL; Tesh VL; Taylor FB
    Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of typical (enteropathic) hemolytic uremic syndrome.
    Bitzan M; Schaefer F; Reymond D
    Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease.
    Pradhan S; Pellino C; MacMaster K; Coyle D; Weiss AA
    Front Cell Infect Microbiol; 2016; 6():114. PubMed ID: 27747196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.
    Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J
    J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways.
    Liu F; Huang J; Sadler JE
    Blood; 2011 Sep; 118(12):3392-8. PubMed ID: 21816831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.